230 related articles for article (PubMed ID: 35402233)
1. Fibroblast Growth Factor Receptor 1-4 Genetic Aberrations as Clinically Relevant Biomarkers in Squamous Cell Lung Cancer.
Moes-Sosnowska J; Chorostowska-Wynimko J
Front Oncol; 2022; 12():780650. PubMed ID: 35402233
[TBL] [Abstract][Full Text] [Related]
2. FGFR1-4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer.
Moes-Sosnowska J; Skupinska M; Lechowicz U; Szczepulska-Wojcik E; Skronska P; Rozy A; Stepniewska A; Langfort R; Rudzinski P; Orlowski T; Popiel D; Stanczak A; Wieczorek M; Chorostowska-Wynimko J
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142417
[TBL] [Abstract][Full Text] [Related]
3. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
[TBL] [Abstract][Full Text] [Related]
4. Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases.
Zhou Z; Liu Z; Ou Q; Wu X; Wang X; Shao Y; Liu H; Yang Y
Cancer Biol Med; 2021 Mar; 18(2):490-501. PubMed ID: 33710807
[TBL] [Abstract][Full Text] [Related]
5. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
[TBL] [Abstract][Full Text] [Related]
6. FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer.
Theelen WS; Mittempergher L; Willems SM; Bosma AJ; Peters DD; van der Noort V; Japenga EJ; Peeters T; Koole K; Šuštić T; Blaauwgeers JL; van Noesel CJ; Bernards R; van den Heuvel MM
J Pathol Clin Res; 2016 Oct; 2(4):223-233. PubMed ID: 27785367
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive pan-cancer study of fibroblast growth factor receptor aberrations in Chinese cancer patients.
Sun Y; Li G; Zhu W; He Q; Liu Y; Chen X; Liu J; Lin J; Han-Zhang H; Yang Z; Lizaso A; Xiang J; Mao X; Liu H; Gao Y
Ann Transl Med; 2020 Oct; 8(20):1290. PubMed ID: 33209870
[TBL] [Abstract][Full Text] [Related]
8. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
Aggarwal C; Redman MW; Lara PN; Borghaei H; Hoffman P; Bradley JD; Newman AJ; Feldman MJ; Minichiello K; Miao J; Mack PC; Papadimitrakopoulou VA; Herbst RS; Kelly K; Gandara DR
J Thorac Oncol; 2019 Oct; 14(10):1847-1852. PubMed ID: 31195180
[TBL] [Abstract][Full Text] [Related]
9. Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures.
Kähkönen TE; Toriseva M; Petruk N; Virta AR; Maher A; Eigéliené N; Kaivola J; Boström P; Koskivuo I; Nees M; Tuomela JM; Ivaska KK; Härkönen PL
Cell Oncol (Dordr); 2021 Feb; 44(1):205-218. PubMed ID: 33119860
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup.
Baldia PH; Maurer A; Heide T; Rose M; Stoehr R; Hartmann A; Williams SV; Knowles MA; Knuechel R; Gaisa NT
Oncotarget; 2016 Nov; 7(44):71429-71439. PubMed ID: 27669755
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors.
Bao Y; Gabrielpillai J; Dietrich J; Zarbl R; Strieth S; Schröck F; Dietrich D
Clin Epigenetics; 2021 Dec; 13(1):228. PubMed ID: 34933671
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma.
Weeden CE; Holik AZ; Young RJ; Ma SB; Garnier JM; Fox SB; Antippa P; Irving LB; Steinfort DP; Wright GM; Russell PA; Ritchie ME; Burns CJ; Solomon B; Asselin-Labat ML
Mol Cancer Ther; 2017 Aug; 16(8):1610-1622. PubMed ID: 28611104
[TBL] [Abstract][Full Text] [Related]
13. FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
Hibi M; Kaneda H; Tanizaki J; Sakai K; Togashi Y; Terashima M; De Velasco MA; Fujita Y; Banno E; Nakamura Y; Takeda M; Ito A; Mitsudomi T; Nakagawa K; Okamoto I; Nishio K
Cancer Sci; 2016 Nov; 107(11):1667-1676. PubMed ID: 27581340
[TBL] [Abstract][Full Text] [Related]
14. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
[TBL] [Abstract][Full Text] [Related]
15. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors.
Salgia R
Cancer Med; 2014 Jun; 3(3):681-92. PubMed ID: 24711160
[TBL] [Abstract][Full Text] [Related]
17. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.
Helsten T; Elkin S; Arthur E; Tomson BN; Carter J; Kurzrock R
Clin Cancer Res; 2016 Jan; 22(1):259-67. PubMed ID: 26373574
[TBL] [Abstract][Full Text] [Related]
18. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
19. High
Sánchez-Guixé M; Hierro C; Jiménez J; Viaplana C; Villacampa G; Monelli E; Brasó-Maristany F; Ogbah Z; Parés M; Guzmán M; Grueso J; Rodríguez O; Oliveira M; Azaro A; Garralda E; Tabernero J; Casanovas O; Scaltriti M; Prat A; Dienstmann R; Nuciforo P; Saura C; Graupera M; Vivancos A; Rodon J; Serra V
Clin Cancer Res; 2022 Jan; 28(1):137-149. PubMed ID: 34593528
[TBL] [Abstract][Full Text] [Related]
20. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP
Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
